Search
Arundic acid
go.drugbank.com/drugs/DB05343InvestigationalArundic acid has been investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Recombinant human plasma gelsolin
go.drugbank.com/drugs/DB15746InvestigationalPlasma gelsolin (pGSN) is a protein found in the blood of healthy individuals which scavenges compounds left over from damaged tissues.
Managlinat dialanetil
go.drugbank.com/drugs/DB05518InvestigationalCS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting enzymes of gluconeogenesis.
Halofantrine
go.drugbank.com/drugs/DB01218ApprovedWithdrawnIt appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. … Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine.
Elinogrel
go.drugbank.com/drugs/DB06350InvestigationalA P2Y12 inhibitor and platelet aggregation inhibitor.
Androstenedione
go.drugbank.com/drugs/DB01536IllicitInvestigationalA delta-4 C19 steroid that is produced not only in the testis, but also in the ovary and the adrenal cortex. … Depending on the tissue type, androstenedione can serve as a precursor to testosterone as well as estrone and estradiol.
KAI-1455
go.drugbank.com/drugs/DB06064ExperimentalIn preclinical studies, KAI-1455 showed a dramatic reduction in infarct size when delivered prior to the ischemic insult. … Several studies have demonstrated that epsilon PKC plays a key role in cytoprotection during periods of ischemia.
Inosine pranobex
go.drugbank.com/drugs/DB13156ApprovedInosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.
rGLP-1
go.drugbank.com/drugs/DB05433ExperimentalGLP-1 is a naturally occurring hormone produced in the intestines in response to food intake. … rGLP-1 is a continuous infusion of glucagon-like peptide 1, or GLP-1, targeted for the treatment of congestive heart failure (CHF) in patients ineligible for transplant.
NM-702
go.drugbank.com/drugs/DB05505InvestigationalTherapeutic options to improve exercise performance in these patients are limited … It is estimated that about 6 million people suffer from intermittent claudication in the USA, with only 10 percent of these people currently receiving treatment.